Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Phase 2 study of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, with gemcitabine/nab-paclitaxel (GnP) in first-line advanced pancreatic ductal adenocarcinoma (PDAC).
Authors
Devalingam Mahalingam
Northwestern University, Chicago, IL
Devalingam Mahalingam , Benedito A. Carneiro , Howard Safran , Steven Francis Powell , Andrew L. Coveler , Elizabeth J. Davis , Andres Cervantes , Vaibhav Sahai , Neeltje Steeghs , Marisol Huerta , Jordan Berlin , Mary Frances Mulcahy , Francis J. Giles , Ludimila Cavalcante , Anwaar Saeed
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03678883
DOI
10.1200/JCO.2022.40.4_suppl.578
Abstract #
578
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Genomic biomarker discovery of first-line gemcitabine/nabpaclitaxel treatment in Chinese advanced pancreatic carcinoma patients.
First Author: Juan Du
Poster
2017 Gastrointestinal Cancers Symposium
Determinants of first-line treatment selection in advanced pancreatic ductal adenocarcinoma (PDAC).
First Author: Hui-Li Wong
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
First Author: Zhiwei Chang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Anlotinib plus TQB2450 (PD-L1 blockade) combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial.
First Author: Shui-Ling Jin